Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor in adult patients with non-cirrhotic NASH with F2–F3 fibrosis
2020-004986-38Phase 3Active
- Sponsor
- Inventiva
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Lanifibranor with Placebo (2 arms). Primary endpoint: Part 1 primary endpoint. Started Jul 2021; status: active.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2020-004986-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004986-38.